GenSight attended the European Society of gene and Cell Therapy congress (ESGCT) in Florence, Italy. 

Jean-Philippe Combal, Chief Operating Officer, gave an oral presentation on Wednesday 19 October, 11:00 am, Session 2b:  Eye stem cell and gene therapy.

OR04  – One-year follow-up study results after IntravitrealrAAV2/2-ND4 (GS010) injection in patients with vision loss due to G11778A ND4 Leber Hereditary Optic Neuropathy.

Wednesday 19 October, Poster Session 1

Poster #P247 – From Non-Human Primates to Patients: Relationship between ocular inflammation and immune responses following intravitreal injection of rAAV2/2-ND4 (GS010), will be also presented.